2021 Rheumatology Year in Review
Jan 08, 2022
Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read Article
Comorbidities Drive Risk of Severe Outcomes with COVID-19
Jan 06, 2022
The current edition of the MMWR from the CDC shows that among those vaccinated against COVID-19, there is a low risk of severe outcomes (hospitalization and death); the highest risk is seen in those with multiple comorbidities.
Read Article
Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children
Jan 05, 2022
Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. A review of proposed management guidelines is compiled in this report, suggesting a unified approach to therapeutic management of MIS-C.
Read Article
Best of 2021: Jack of All Subspecialties
Dec 31, 2021
It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen
Read Article
Best of 2021: Perspectives on CV safety: JAKi (Tofacitinib) and TNF inhibitors
Dec 31, 2021
Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.
Read Article
Best of 2021: FDA Puts Boxed Warnings on JAK Inhibitors
Dec 30, 2021
Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before
Read ArticleBest of 2021: Tofacitinib Safety Concerns
Dec 29, 2021
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Read Article
Best of 2021: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease
Dec 21, 2021
Genentech announced March 4th that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.
Read Article
CDC Panel Recommends mRNA COVID Vaccines Over J&J Vaccine
Dec 17, 2021
The U.S. Centers for Disease Control and Prevention (CDC) yesterday recommended Americans has recommended the two authorised mRNA COVID-19 vaccines over Johnson & Johnson's adenovirus COVID-19 vaccine, primarily due to the rare reports of thrombosis with thrombocytopenia syndrome (TTS).
Read ArticleFDA Puts Boxed Warnings on JAK Inhibitors
Dec 06, 2021
Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before
Read Article
Prolonging the Controversy of Hydroxychloroquine
Nov 30, 2021
Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.
Read Article
Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.https://t.co/O90HInaS7z https://t.co/MdHVyxfkaW
Links:
Dr. John Cush @RheumNow( View Tweet )
Nov 29, 2021
ICYMI: Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the #ACR21 annual meeting.https://t.co/5BrxeJBWM2 https://t.co/m8CqyJ1L7A
Links:
Dr. John Cush @RheumNow( View Tweet )
Nov 28, 2021
Dr. Janet Pope and Dr. Jeffrey Sparks discuss the importance of lung and several lung-related abstracts presented at the ACR21 annual meeting. https://t.co/s5sl6tdKwP
Links:
Dr. John Cush @RheumNow( View Tweet )
Nov 26, 2021
Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush reviews poster #1100 presented at the #ACR21 annual meeting.https://t.co/2YGPHT3AAO https://t.co/lLRKnxB04a
Links:
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2021
Long Term Steroid Use in RA - Matters of the Heart: Dr. Mrinalini Dey ( @DrMiniDey) discusses abstract #1428 presented at the #ACR21 annual meeting.https://t.co/E6RSlPAuRT https://t.co/QBhKD855aH
Links:
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2021
ICYMI: Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitorshttps://t.co/g5FirIK9Af https://t.co/63s7IaKhl7
Links:
Dr. John Cush @RheumNow( View Tweet )
Nov 21, 2021
Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors
Nov 15, 2021
Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.
Read ArticleRheumNow Podcast - ACR 2021 Rehash (the good stuff..)
Nov 12, 2021
The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
Read Article
RA: Cardiovascular Risk Stratification and Potential Predictors of Risk
Nov 11, 2021
Early cardiovascular disease assessment and management is critical at diagnosis in patients with Rheumatoid Arthritis (RA). Patients with RA have a known increased risk of developing cardiovascular disease (CVD) due to a higher incidence of traditional cardiovascular (CV) risks such as
Read Article
Cognitive Impairment in Patients with Rheumatoid Arthritis
Nov 10, 2021
Evidence suggests that RA patients are at increased risk for cognitive impairment. This is likely mediated by certain factors, including chronic inflammation and accelerated atherosclerosis. In the clinical setting, it is important to identify RA patients at increased risk for cognitive
Read Article
ACR21 – Day 3 Report
Nov 09, 2021
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.
Read Article
Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch
Janet Pope @Janetbirdope( View Tweet )
Nov 09, 2021
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
#ACR21 Ab#1939: Tofa CV Outcome (STAR-RA)
▶️Pooled data does not show ⬆️ risk of CVD
▶️Trend in pts w prior CVD -HR 1.27 (0.95-1.7), cannot r/o CVD risk in pts w risk factors
Less clear than oral surveillance data, but concerns in those w riskshttps://t.co/JOKNyYVZfX @Rheumnow https://t.co/GGYJfxcqhc
Links:
Eric Dein @ericdeinmd( View Tweet )
Nov 09, 2021
Recent Blogs
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
Read Post
